"Done in a snap: disinfected in seconds!" – Groundbreaking Sporosan® disinfection technology unveiled at BZH Congress
"Imagine an active substance that forms in a snap of the fingers, reliably disinfects in seconds, and then breaks down almost completely,” says Marijan N. Simundic, who heads the innovation project at Meiko, summarising the key benefits of Sporosan®. This new disinfection process delivers what the sector has long demanded: high-performance, sporicidal disinfection that does not require prolonged application times and that offers maximum safety for users as well as comprehensive infection protection for patients and residents.
Experts can discover Sporosan® and its hygiene vision first-hand from 8–10 October 2025 at the Freiburg Infectiology & Hygiene Congress organised by BZH, a German consulting centre for infection prevention and control in healthcare. The programme includes a live demonstration of the product’s disinfection performance, along with a scientific context‑setting presentation on day one of the congress.
Technological breakthrough grounded in science
The active substance in Sporosan® is peroxynitrous acid (ONOOH), a short-lived yet exceptionally powerful compound. A patented two-component system generates ONOOH exactly precisely when needed, delivering verified efficacy against:
- bacteria (including multidrug‑resistant strains)
- enveloped and non-enveloped viruses
- yeasts and moulds
- mycobacteria
- endospores (e.g. C. difficile spores)
A number of study reports from accredited laboratories[1] confirm the product's performance. “Peroxynitrous acid survives for only about a second before it breaks down. That made it tricky to handle at first, but it also makes it inherently safe and eco-friendly. Our aim was to harness the benefits of this molecule in a robust, real-world process – and that's exactly what Sporosan® does,“ says Dr. Ansgar Schmidt-Bleker, CEO and co-founder of Nebula Biocides GmbH.
Wide range of applications: from surfaces to bedpan-washers
This new technology offers an impressively broad scope: Sporosan® is suitable for disinfecting surfaces, for manually reprocessing medical devices and for use in automated washer-disinfectors.
A joint device study on bedpan washers – a notoriously challenging area – is already under way with Meiko. "But our vision is much broader. Sporosan® lets us rethink disinfection from the ground up, opening entirely new pathways for professional hygiene," says Simundic.
Background: tackling an invisible health risk
Sporosan® was developed specifically to combat spore-forming pathogens such as C. difficile –identified by the Robert Koch Institute as a leading cause of healthcare‑associated infections in Germany, and cited by the US Department of Health and Human Services as the most common cause in the United States. It is classified accordingly as an “Urgent Threat” by the US Centers for Disease Control and Prevention (CDC)[2]. The rapid, complete inactivation of such pathogens is therefore not only a technical challenge but also a critical priority for the healthcare sector.
"The ability to neutralise stubborn spores like C. difficile in seconds enables entirely new workflows – especially in cases where time is critical. Sporosan® sets a new standard of protection, particularly in high-burden care environments,” says Dr Jörn Winter, co-developer and CEO of Nebula Biocides GmbH.
Find out more: www.meiko.com/sporosan
Note:
Sporosan® concentrate is currently undergoing regulatory approval. Conformity with the Medical Device Regulation (MDR, EU 2017/745) has not yet been granted.
[1] See the study reports at: https://nebula-biocides.de/DE/meikoactive8100.php
[2] Source: Antibiotic Resistance Threats in the United States, 2019, pp. 4 and 65ff